Guided Therapeutics closes $3.3M bridge financing, exchanges Auctus debt, targets FDA study completion

GUIDED THERAPEUTICS INC

Raised ~$3.3M via 6.6M shares at $0.50 each, plus four-year warrants for 6.6M shares at $0.50 and 6.6M at $0.65.
Auctus exchanged $1.06M debt and 8.78M warrants for $1.95M in units (3.9M shares, 3.9M warrants at $0.50 and $0.65); residual $490K debt over 18 months.
Net proceeds ~$3.2M; primary use to fund clinical study data for FDA approval of LuViva Advanced Cervical Scan, also support international sales and reduce debt.
Stockholders' equity nearly break-even; Company to withdraw S-1/A for Nasdaq uplist and reapply when market conditions improve.
Investors include board members Richard Blumberg, Michael James, John Imhoff.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.